Author:
van Zeijl M.C.T.,de Wreede L.C.,van den Eertwegh A.J.M.,Wouters M.W.J.M.,Jochems A.,Schouwenburg M.G.,Aarts M.J.B.,van Akkooi A.C.J.,van den Berkmortel F.W.P.J.,de Groot J.W.B.,Hospers G.A.P.,Kapiteijn E.,Piersma D.,van Rijn R.S.,Suijkerbuijk K.P.M.,ten Tije A.J.,van der Veldt A.A.M.,Vreugdenhil G.,van der Hoeven J.J.M.,Haanen J.B.A.G.
Funder
The Netherlands Organization for Health Research and Development
Bristol-Myers Squibb
Novartis
Pierre Fabre
Reference30 articles.
1. Final version of 2009 AJCC melanoma staging and classification;Balch;J Clin Oncol,2009
2. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials;Korn;J Clin Oncol,2008
3. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial;Long;Lancet,2015
4. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial;Ascierto;Lancet Oncol,2016
5. Abstract CT001: durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial;Hodi,2016
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献